Results summary | View all lists in GO:BiolProc | View all genes in C05AA.profile.ud50 |
anatomical structure development The biological process whose specific outcome is the progression of an anatomical structure from an initial condition to its mature state. This process begins with the formation of the structure and ends with the mature structure, whatever form that may be including its natural destruction. An anatomical structure is any biological entity that occupies space and is distinguished from its surroundings. Anatomical structures can be macroscopic such as a carpel, or microscopic such as an acrosome. enrichment: 1.93-fold |
|||||||||||||
Probe ID | Name | G | T | D | X | E | P | R | C | S | Description | ||
218502_S_AT | TRPS1 | T | D | R | trichorhinophalangeal syndrome I | ||||||||
215073_S_AT | NR2F2 | D | E | R | S | nuclear receptor subfamily 2, group F, member 2 | |||||||
219799_S_AT | DHRS9 | E | dehydrogenase/reductase (SDR family) member 9 | ||||||||||
203140_AT | BCL6 | G | D | X | R | C | S | B-cell CLL/lymphoma 6 (zinc finger protein 51) | |||||
213139_AT | SNAI2 | D | R | C | snail homolog 2 (Drosophila) | ||||||||
212501_AT | CEBPB | G | D | X | P | R | CCAAT/enhancer binding protein (C/EBP), beta | ||||||
213552_AT | GLCE | E | P | glucuronic acid epimerase | |||||||||
217427_S_AT | HIRA | D | R | HIR histone cell cycle regulation defective homolog A (S. cerevisiae) | |||||||||
215990_S_AT | BCL6 | G | D | X | R | C | S | B-cell CLL/lymphoma 6 (zinc finger protein 51) | |||||
209185_S_AT | IRS2 | G | D | E | S | insulin receptor substrate 2 | |||||||
203358_S_AT | EZH2 | D | P | R | enhancer of zeste homolog 2 (Drosophila) | ||||||||
203373_AT | SOCS2 | G | S | suppressor of cytokine signaling 2 | |||||||||
207980_S_AT | CITED2 | D | R | S | Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 | ||||||||
211082_X_AT | MARK2 | D | P | S | MAP/microtubule affinity-regulating kinase 2 | ||||||||
200878_AT | EPAS1 | D | X | R | S | endothelial PAS domain protein 1 | |||||||
221009_S_AT | ANGPTL4 | G | D | X | E | S | angiopoietin-like 4 | ||||||
218559_S_AT | MAFB | D | R | v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) | |||||||||
208960_S_AT | KLF6 | D | R | S | Kruppel-like factor 6 | ||||||||
201324_AT | EMP1 | G | D | epithelial membrane protein 1 | |||||||||
37152_AT | PPARD | G | T | D | E | R | C | S | peroxisome proliferator-activated receptor delta | ||||
201341_AT | ENC1 | D | ectodermal-neural cortex (with BTB-like domain) | ||||||||||
208937_S_AT | ID1 | D | R | S | inhibitor of DNA binding 1, dominant negative helix-loop-helix protein | ||||||||
209120_AT | NR2F2 | D | E | R | S | nuclear receptor subfamily 2, group F, member 2 | |||||||
209184_S_AT | IRS2 | G | D | E | S | insulin receptor substrate 2 | |||||||
201340_S_AT | ENC1 | D | ectodermal-neural cortex (with BTB-like domain) | ||||||||||
207023_X_AT | KRT10 | D | keratin 10 (epidermolytic hyperkeratosis; keratosis palmaris et plantaris) | ||||||||||
211833_S_AT | BAX | G | T | D | X | P | S | BCL2-associated X protein |